0
USD
U.S. (TOLL FREE)
+1 (425) 388-2538
Automative

0
U.S. (TOLL FREE)
+1 (425) 388-2538
Europe Digital Therapeutics Market by Application (Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS) Disease, Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID), andOthers),Product Type (Software and Device), and Sales Channel (Business-to-Business(B2B) and Business-to-Consumer (B2C)): Opportunity Analysis and Industry Forecast, 2019–2026
Published Date: August 2020
|
Report Code: ALLI-Manu-0A22
Home | Category |Health
Europe Digital Therapeutics Market

Europe Digital Therapeutics Market by Application (Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS) Disease, Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID), andOthers),Product Type (Software and Device), and Sales Channel (Business-to-Business(B2B) and Business-to-Consumer (B2C)): Opportunity Analysis and Industry Forecast, 2019–2026

Code: ALLI-Manu-0A22
Report
August 2020
159 Pages
Allied Market Research
Region:
Description
Table of Content
Tables & Figures

Europe Digital Therapeutics Market Overview:

The Europe digital therapeutics market size was valued at USD 0.50 Billion in 2018 and is expected to reach USD 2.27 Billion by 2026 with a CAGR of 20.6% during the forecast period.

Digital therapeutics is a subdivision of digital health,not all digital health solutions are digital therapeutics. The difference between digital health and digital therapeutics is based on the clinical outcomes for patients. For instance, digital therapeutics does not include consumer health-oriented technologies such as step-counters and calorie-counters. It’s a new class of healthcare products that uses digital technology to prevent, manage, or treat medical conditions. In addition, it utilizes digital health technologies to treat a psychological condition.Hence, such factors boost the Europedigital therapeutics market share across the world. 

Rise in adoption of smart phones and tablets, coupled with healthcare apps; growth in need to control healthcare costs; and rise in incidences of chronic diseases drive the demand for digital therapeutics in Europe. However, lack of awareness regarding digital therapeutics in developing countries and patient data privacy concerns restrain the market growth. On the contrary, high growth opportunities in untapped markets are expected to provide significant profitable opportunities for manufacturers in the digital therapeutics industry.

By using digital therapeutics, a patient can track medication usage, blood sugar level, and other factors throughout the day to improve overall health. Hence, rise in demand for cost-effective healthcare services, surge in adoption of smart phone healthcare applications, and increase in R&D of smart healthcare devices such as fitness bands, VR headsets, sleep inducers, and smart inhalers help people track and treat major health problems at a lower cost, which ultimately boosts the market growth.

Based on Application, Europe Digital Therapeutics Market is segmented into Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS) Disease, Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID), and Others. Depending upon product Type, the market is divided into software and device. By sales channel, the market is bifurcated into business-to-business (B2B) and business-to-consumer (B2C). Region wise, the market is studies across European countries including, UK, Germany, France, Italy, Spain, Russia, and Rest of Europe.

Applicationsegment review

On the basis of application, the digital therapeutics market is segmented into diabetes, obesity, cardiovascular disease, central nervous system disease, respiratory disease, smoking cessation, gastrointestinal disorder, and others. The diabetes segment was the major revenue contributor in 2018, and is anticipated to continue this trend during the forecast period, owing to high prevalence of diabetes. However, the obesity segment is projected to exhibit the highest growth during the forecast period. This is attributed to the rise in number of overweight populations,thereby increasing the number of chronic diseases due to obesity. In addition, better accessibility of digital therapeutics software applicationthat help patients to maintain their proper diet as well as track health data and daily physical activities. Moreover, the software provides regular online assistance from certified doctors, which is expectedto help in reducing the prevalence of obesity in the future.

Productsegment review

Depending on product, the digital the rapeutics market is categorized into software and devices. The software segment is projected to exhibit the highest growth during the forecast period. This is attributed tothe rise in demand for reducing healthcare costsacross Europe.This gives immense opportunities to developers to use existing software and develop newand advanced features to make them more effective and affordable.Thus,is anticipated to increase the digital therapeutics market size in the future.

The report provides a comprehensive analysis of the key players operating in the Europedigital therapeuticsmarket,namelyAda Health GmbH, CogniFit, Caterna Vision GmbH, Fitbit, Inc. (Twine Health, Inc.), Kaia Health, Medtronic Plc., Novartis International AG (Pear Therapeutics, Inc.), ResMed, Inc. (Propeller Health), Sonormed GmbH, and Voluntis, Inc.

The other players in the value chain include (profiles not included in the report) GlaxoSmithKline, Veeva Systems, and Syneos Health.

Key Benefits For Stakeholders

  • This report provides a detailed quantitative analysis of the current digital therapeutics markettrends and forecast estimations from 2018to 2026, which assists to identify the prevailing market opportunities. 
  • An in-depth digital therapeuticsmarket analysisincludes analysis ofEurope, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate this region-specific plan.
  • A comprehensive analysis of factors that drive and restrain the digital therapeuticsmarket growth of the Europeis provided.
  • The projections in this report are made by analyzing the current trends and future market potential from2019 to 2026, in terms of value.
  • Key market players within the digital therapeutics market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of Europedigital therapeuticsmarket.

Key Market Segments

By Application

  • Diabetes
  • Obesity
  • Cardiovascular Disease (CVD)
  • Central Nervous System (CNS) Disease
  • Respiratory Disease
  • Smoking Cessation
  • Gastrointestinal Disorder (GID)
  • Others

By Product Type

  • Software
  • Device

By Product Type

  • Business-to-Business (B2B)
    • Employer
    • Healthcare Provider
    • Others
  • Business-to-Consumer (B2C)
  • Patient
  • Caregiver

By Country

  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.2.3.Top player positioning, 2018

3.3.Porter’s five forces analysis
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increase in adoption of smartphones and tablets coupled with healthcare apps
3.4.1.2.Growth in need to control healthcare costs
3.4.1.3.Rise in incidences of chronic diseases

3.4.2.Restraints

3.4.2.1.Lack of awareness regarding digital therapeutics in developing countries
3.4.2.2.Patient data privacy concerns

3.4.3.Opportunity

3.4.3.1.Emerging markets offer significant growth opportunities

CHAPTER 4:EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION

4.1.Overview

4.1.1.Market size and forecast

4.2.Diabetes

4.2.1.Key market trends and growth opportunities
4.2.2.Market analysis, by country

4.3.Obesity

4.3.1.Key market trends and growth opportunities
4.3.2.Market analysis, by country

4.4.Cardiovascular diseases

4.4.1.Key market trends and growth opportunities
4.4.2.Market analysis, by country

4.5.Central nervous system (CNS) diseases

4.5.1.Key market trends and growth opportunities
4.5.2.Market analysis, by country

4.6.Gastrointestinal disorder

4.6.1.Key market trends and growth opportunities
4.6.2.Market analysis, by country

4.7.Respiratory diseases

4.7.1.Key market trends and growth opportunities
4.7.2.Market analysis, by country

4.8.Smoking cessation

4.8.1.Key market trends and growth opportunities
4.8.2.Market analysis, by country

4.9.Others

4.9.1.Key market trends and growth opportunities
4.9.2.Market analysis, by country

CHAPTER 5:EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT

5.1.Overview

5.1.1.Market size and forecast

5.2.Software

5.2.1.Market analysis, by country

5.3.Devices

5.3.1.Market analysis, by country

CHAPTER 6:EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL

6.1.Overview

6.1.1.Market size and forecast

6.2.Business-to-business (B2B)

6.2.1.Market size and forecast, by type

6.2.1.1.Employer

6.2.1.1.1.Market size and forecast

6.2.1.2.Healthcare Providers

6.2.1.2.1.Market size and forecast

6.2.1.3.Others

6.2.1.3.1.Market size and forecast

6.2.2.Market analysis, by country

6.3.Business-to-consumers (B2C)

6.3.1.Market size and forecast, by type

6.3.1.1.Patients

6.3.1.1.1.Market size and forecast

6.3.1.2.Caregivers

6.3.1.2.1.Market size and forecast

6.3.2.Market analysis, by country

CHAPTER 7:EUROPE DIGITAL THERAPEUTICS MARKET, BY COUNTRY

7.1.Overview
7.2.Key market trends, growth factors, and opportunities
7.3.Europe digital therapeutics market, by country

7.3.1.UK digital therapeutics market, by application
7.3.2.UK digital therapeutics market, by product type
7.3.3.UK digital therapeutics market, by sales channel
7.3.4.Germany digital therapeutics market, by application
7.3.5.Germany digital therapeutics market, by product type
7.3.6.Germany digital therapeutics market, by sales channel
7.3.7.France digital therapeutics market, by application
7.3.8.France digital therapeutics market, by product type
7.3.9.France digital therapeutics market, by sales channel
7.3.10.Italy digital therapeutics market, by application
7.3.11.Italy digital therapeutics market, by product type
7.3.12.Italy digital therapeutics market, by sales channel
7.3.13.Spain digital therapeutics market, by application
7.3.14.Spain digital therapeutics market, by product type
7.3.15.Spain digital therapeutics market, by sales channel
7.3.16.Russia digital therapeutics market, by application
7.3.17.Russia digital therapeutics market, by product type
7.3.18.Russia digital therapeutics market, by sales channel
7.3.19.Rest of Europe digital therapeutics market, by application
7.3.20.Rest of Europe digital therapeutics market, by product type
7.3.21.Rest of Europe digital therapeutics market, by sales channel

7.4.Europe digital therapeutics market, by application
7.5.Europe digital therapeutics market, by product type
7.6.Europe digital therapeutics market, by sales channel

CHAPTER 8:COMPANY PROFILES

8.1.ADA HEALTH GMBH

8.1.1.Company overview
8.1.2.Product portfolio
8.1.3.Key strategic moves and developments

8.2.COGNIFIT

8.2.1.Company overview
8.2.2.Operating business segments
8.2.3.Product portfolio
8.2.4.Key strategic moves and developments

8.3.CATERNA VISION GMBH

8.3.1.Company overview
8.3.2.Operating business segments
8.3.3.Product portfolio

8.4.FITBIT, INC. (TWINE HEALTH, INC.)

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Product portfolio
8.4.4.Business performance

8.5.KAIA HEALTH

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio

8.6.MEDTRONIC PLC.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance

8.7.NOVARTIS INTERNATIONAL AG (PEAR THERAPEUTICS, INC.)

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.RESMED, INC. (PROPELLER HEALTH)

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.SONORMED GMBH

8.9.1.Company overview
8.9.2.Product portfolio

8.10.VOLUNTIS, INC.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 02.EUROPE DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 03.EUROPE DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 04.EUROPE DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 05.EUROPE DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM (CNS) DISEASES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 06.EUROPE DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDER, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 07.EUROPE DIGITAL THERAPEUTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 08.EUROPE DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 09.EUROPE DIGITAL THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 10.EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 11.DIGITAL THERAPEUTIC APPLICATIONS AND SOFTWARE PLATFORMS
TABLE 12.EUROPE DIGITAL THERAPEUTICS MARKET FOR SOFTWARE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 13.EUROPE DIGITAL THERAPEUTICS MARKET FOR DEVICES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 14.EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 15.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY TYPE, 2018–2026 ($MILLION)
TABLE 16.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 17.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY TYPE, 2018–2026 ($MILLION)
TABLE 18.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO- CONSUMERS, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 19.EUROPE DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 20.UK DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 21.UK DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 22.UK DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 23.GERMANY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 24.GERMANY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 25.GERMANY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 26.FRANCE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 27.FRANCE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 28.FRANCE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 29.ITALY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 30.ITALY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 31.ITALY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 32.SPAIN DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 33.SPAIN DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 34.SPAIN DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 35.RUSSIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 36.RUSSIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 37.RUSSIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 38.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 39.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 40.REST OF DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 41.DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 42.DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 43.DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 44.ADA: COMPANY SNAPSHOT
TABLE 45.ADA: PRODUCT PORTFOLIO
TABLE 46.COGNIFIT: COMPANY SNAPSHOT
TABLE 47.COGNIFIT: OPERATING SEGMENT:
TABLE 48.COGNIFIT: PRODUCT PORTFOLIO
TABLE 49.CATERNA: COMPANY SNAPSHOT
TABLE 50.CATERNA: PRODUCT PORTFOLIO
TABLE 51.FITBIT: COMPANY SNAPSHOT
TABLE 52.FITBIT: PRODUCT PORTFOLIO
TABLE 53.KAIA HEALTH: COMPANY SNAPSHOT
TABLE 54.KAIA: OPERATING SEGMENT:
TABLE 55.KAIA: PRODUCT PORTFOLIO
TABLE 56.MEDTRONIC: COMPANY SNAPSHOT
TABLE 57.MEDTRONIC: OPERATING SEGMENTS
TABLE 58.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 59.NOVARTIS: COMPANY SNAPSHOT
TABLE 60.NOVARTIS: OPERATING SEGMENTS
TABLE 61.NOVARTIS: PRODUCT PORTFOLIO
TABLE 62.RESMED: COMPANY SNAPSHOT
TABLE 63.RESMED: OPERATING SEGMENTS
TABLE 64.RESMED: PRODUCT PORTFOLIO
TABLE 65.SONORMED: COMPANY SNAPSHOT
TABLE 66.SONORMED: PRODUCT PORTFOLIO
TABLE 67.VOLUNTIS: COMPANY SNAPSHOT
TABLE 68.VOLUNTIS: OPERATING SEGMENTS
TABLE 69.VOLUNTIS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.DIGITAL THERAPEUTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS IN DIGITAL THERAPEUTICSS MARKET, 2018
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2019*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2019* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2019*
FIGURE 06.TOP PLAYER POSITIONING, 2018
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.HIGH BARGAINING POWER OF BUYERS
FIGURE 09.LOW THREAT OF SUBSTITUTION
FIGURE 10.MODERATE THREAT OF NEW ENTRANT
FIGURE 11.MODERATE COMPETITIVE RIVALRY
FIGURE 12.EUROPE DIGITAL THERAPEUTICS MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 13.EUROPE DIGITAL THERAPEUTICS MARKET BY APPLICATION
FIGURE 14.EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT
FIGURE 15.EUROPE DIGITAL THERAPEUTICS MARKET BY SALES CHANNEL
FIGURE 16.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY EMPLOYER,  2018–2026 ($MILLION)
FIGURE 17.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY HEALTHCARE PROVIDERS, 2018–2026 ($MILLION)
FIGURE 18.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY OTHERS,  2018–2026 ($MILLION)
FIGURE 19.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY PATIENTS, 2018–2026 ($MILLION)
FIGURE 20.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY CAREGIVERS, 2018–2026 ($MILLION)
FIGURE 21.FITBIT: NET SALES, 2016–2018 ($MILLION)
FIGURE 22.FITBIT: NET SALES BY REGION, 2018 (%)
FIGURE 23.MEDTRONIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 24.MEDTRONIC: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 25.MEDTRONIC: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 26.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 29.RESMED: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.RESMED: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 31.RESMED: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 32.VOLUNTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 33.VOLUNTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 34.VOLUNTIS: REVENUE SHARE BY REGION, 2018 (%)

Europe Digital Therapeutics Market Overview:

The Europe digital therapeutics market size was valued at USD 0.50 Billion in 2018 and is expected to reach USD 2.27 Billion by 2026 with a CAGR of 20.6% during the forecast period.

Digital therapeutics is a subdivision of digital health,not all digital health solutions are digital therapeutics. The difference between digital health and digital therapeutics is based on the clinical outcomes for patients. For instance, digital therapeutics does not include consumer health-oriented technologies such as step-counters and calorie-counters. It’s a new class of healthcare products that uses digital technology to prevent, manage, or treat medical conditions. In addition, it utilizes digital health technologies to treat a psychological condition.Hence, such factors boost the Europedigital therapeutics market share across the world. 

Rise in adoption of smart phones and tablets, coupled with healthcare apps; growth in need to control healthcare costs; and rise in incidences of chronic diseases drive the demand for digital therapeutics in Europe. However, lack of awareness regarding digital therapeutics in developing countries and patient data privacy concerns restrain the market growth. On the contrary, high growth opportunities in untapped markets are expected to provide significant profitable opportunities for manufacturers in the digital therapeutics industry.

By using digital therapeutics, a patient can track medication usage, blood sugar level, and other factors throughout the day to improve overall health. Hence, rise in demand for cost-effective healthcare services, surge in adoption of smart phone healthcare applications, and increase in R&D of smart healthcare devices such as fitness bands, VR headsets, sleep inducers, and smart inhalers help people track and treat major health problems at a lower cost, which ultimately boosts the market growth.

Based on Application, Europe Digital Therapeutics Market is segmented into Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS) Disease, Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID), and Others. Depending upon product Type, the market is divided into software and device. By sales channel, the market is bifurcated into business-to-business (B2B) and business-to-consumer (B2C). Region wise, the market is studies across European countries including, UK, Germany, France, Italy, Spain, Russia, and Rest of Europe.

Applicationsegment review

On the basis of application, the digital therapeutics market is segmented into diabetes, obesity, cardiovascular disease, central nervous system disease, respiratory disease, smoking cessation, gastrointestinal disorder, and others. The diabetes segment was the major revenue contributor in 2018, and is anticipated to continue this trend during the forecast period, owing to high prevalence of diabetes. However, the obesity segment is projected to exhibit the highest growth during the forecast period. This is attributed to the rise in number of overweight populations,thereby increasing the number of chronic diseases due to obesity. In addition, better accessibility of digital therapeutics software applicationthat help patients to maintain their proper diet as well as track health data and daily physical activities. Moreover, the software provides regular online assistance from certified doctors, which is expectedto help in reducing the prevalence of obesity in the future.

Productsegment review

Depending on product, the digital the rapeutics market is categorized into software and devices. The software segment is projected to exhibit the highest growth during the forecast period. This is attributed tothe rise in demand for reducing healthcare costsacross Europe.This gives immense opportunities to developers to use existing software and develop newand advanced features to make them more effective and affordable.Thus,is anticipated to increase the digital therapeutics market size in the future.

The report provides a comprehensive analysis of the key players operating in the Europedigital therapeuticsmarket,namelyAda Health GmbH, CogniFit, Caterna Vision GmbH, Fitbit, Inc. (Twine Health, Inc.), Kaia Health, Medtronic Plc., Novartis International AG (Pear Therapeutics, Inc.), ResMed, Inc. (Propeller Health), Sonormed GmbH, and Voluntis, Inc.

The other players in the value chain include (profiles not included in the report) GlaxoSmithKline, Veeva Systems, and Syneos Health.

Key Benefits For Stakeholders

  • This report provides a detailed quantitative analysis of the current digital therapeutics markettrends and forecast estimations from 2018to 2026, which assists to identify the prevailing market opportunities. 
  • An in-depth digital therapeuticsmarket analysisincludes analysis ofEurope, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate this region-specific plan.
  • A comprehensive analysis of factors that drive and restrain the digital therapeuticsmarket growth of the Europeis provided.
  • The projections in this report are made by analyzing the current trends and future market potential from2019 to 2026, in terms of value.
  • Key market players within the digital therapeutics market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of Europedigital therapeuticsmarket.

Key Market Segments

By Application

  • Diabetes
  • Obesity
  • Cardiovascular Disease (CVD)
  • Central Nervous System (CNS) Disease
  • Respiratory Disease
  • Smoking Cessation
  • Gastrointestinal Disorder (GID)
  • Others

By Product Type

  • Software
  • Device

By Product Type

  • Business-to-Business (B2B)
    • Employer
    • Healthcare Provider
    • Others
  • Business-to-Consumer (B2C)
  • Patient
  • Caregiver

By Country

  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

 

Read More

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.2.3.Top player positioning, 2018

3.3.Porter’s five forces analysis
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increase in adoption of smartphones and tablets coupled with healthcare apps
3.4.1.2.Growth in need to control healthcare costs
3.4.1.3.Rise in incidences of chronic diseases

3.4.2.Restraints

3.4.2.1.Lack of awareness regarding digital therapeutics in developing countries
3.4.2.2.Patient data privacy concerns

3.4.3.Opportunity

3.4.3.1.Emerging markets offer significant growth opportunities

CHAPTER 4:EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION

4.1.Overview

4.1.1.Market size and forecast

4.2.Diabetes

4.2.1.Key market trends and growth opportunities
4.2.2.Market analysis, by country

4.3.Obesity

4.3.1.Key market trends and growth opportunities
4.3.2.Market analysis, by country

4.4.Cardiovascular diseases

4.4.1.Key market trends and growth opportunities
4.4.2.Market analysis, by country

4.5.Central nervous system (CNS) diseases

4.5.1.Key market trends and growth opportunities
4.5.2.Market analysis, by country

4.6.Gastrointestinal disorder

4.6.1.Key market trends and growth opportunities
4.6.2.Market analysis, by country

4.7.Respiratory diseases

4.7.1.Key market trends and growth opportunities
4.7.2.Market analysis, by country

4.8.Smoking cessation

4.8.1.Key market trends and growth opportunities
4.8.2.Market analysis, by country

4.9.Others

4.9.1.Key market trends and growth opportunities
4.9.2.Market analysis, by country

CHAPTER 5:EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT

5.1.Overview

5.1.1.Market size and forecast

5.2.Software

5.2.1.Market analysis, by country

5.3.Devices

5.3.1.Market analysis, by country

CHAPTER 6:EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL

6.1.Overview

6.1.1.Market size and forecast

6.2.Business-to-business (B2B)

6.2.1.Market size and forecast, by type

6.2.1.1.Employer

6.2.1.1.1.Market size and forecast

6.2.1.2.Healthcare Providers

6.2.1.2.1.Market size and forecast

6.2.1.3.Others

6.2.1.3.1.Market size and forecast

6.2.2.Market analysis, by country

6.3.Business-to-consumers (B2C)

6.3.1.Market size and forecast, by type

6.3.1.1.Patients

6.3.1.1.1.Market size and forecast

6.3.1.2.Caregivers

6.3.1.2.1.Market size and forecast

6.3.2.Market analysis, by country

CHAPTER 7:EUROPE DIGITAL THERAPEUTICS MARKET, BY COUNTRY

7.1.Overview
7.2.Key market trends, growth factors, and opportunities
7.3.Europe digital therapeutics market, by country

7.3.1.UK digital therapeutics market, by application
7.3.2.UK digital therapeutics market, by product type
7.3.3.UK digital therapeutics market, by sales channel
7.3.4.Germany digital therapeutics market, by application
7.3.5.Germany digital therapeutics market, by product type
7.3.6.Germany digital therapeutics market, by sales channel
7.3.7.France digital therapeutics market, by application
7.3.8.France digital therapeutics market, by product type
7.3.9.France digital therapeutics market, by sales channel
7.3.10.Italy digital therapeutics market, by application
7.3.11.Italy digital therapeutics market, by product type
7.3.12.Italy digital therapeutics market, by sales channel
7.3.13.Spain digital therapeutics market, by application
7.3.14.Spain digital therapeutics market, by product type
7.3.15.Spain digital therapeutics market, by sales channel
7.3.16.Russia digital therapeutics market, by application
7.3.17.Russia digital therapeutics market, by product type
7.3.18.Russia digital therapeutics market, by sales channel
7.3.19.Rest of Europe digital therapeutics market, by application
7.3.20.Rest of Europe digital therapeutics market, by product type
7.3.21.Rest of Europe digital therapeutics market, by sales channel

7.4.Europe digital therapeutics market, by application
7.5.Europe digital therapeutics market, by product type
7.6.Europe digital therapeutics market, by sales channel

CHAPTER 8:COMPANY PROFILES

8.1.ADA HEALTH GMBH

8.1.1.Company overview
8.1.2.Product portfolio
8.1.3.Key strategic moves and developments

8.2.COGNIFIT

8.2.1.Company overview
8.2.2.Operating business segments
8.2.3.Product portfolio
8.2.4.Key strategic moves and developments

8.3.CATERNA VISION GMBH

8.3.1.Company overview
8.3.2.Operating business segments
8.3.3.Product portfolio

8.4.FITBIT, INC. (TWINE HEALTH, INC.)

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Product portfolio
8.4.4.Business performance

8.5.KAIA HEALTH

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio

8.6.MEDTRONIC PLC.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance

8.7.NOVARTIS INTERNATIONAL AG (PEAR THERAPEUTICS, INC.)

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.RESMED, INC. (PROPELLER HEALTH)

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.SONORMED GMBH

8.9.1.Company overview
8.9.2.Product portfolio

8.10.VOLUNTIS, INC.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

Read More

LIST OF TABLES

TABLE 01.EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 02.EUROPE DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 03.EUROPE DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 04.EUROPE DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 05.EUROPE DIGITAL THERAPEUTICS MARKET FOR CENTRAL NERVOUS SYSTEM (CNS) DISEASES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 06.EUROPE DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDER, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 07.EUROPE DIGITAL THERAPEUTICS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 08.EUROPE DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 09.EUROPE DIGITAL THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 10.EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 11.DIGITAL THERAPEUTIC APPLICATIONS AND SOFTWARE PLATFORMS
TABLE 12.EUROPE DIGITAL THERAPEUTICS MARKET FOR SOFTWARE, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 13.EUROPE DIGITAL THERAPEUTICS MARKET FOR DEVICES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 14.EUROPE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 15.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY TYPE, 2018–2026 ($MILLION)
TABLE 16.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 17.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY TYPE, 2018–2026 ($MILLION)
TABLE 18.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO- CONSUMERS, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 19.EUROPE DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 20.UK DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 21.UK DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 22.UK DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 23.GERMANY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 24.GERMANY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 25.GERMANY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 26.FRANCE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 27.FRANCE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 28.FRANCE DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 29.ITALY DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 30.ITALY DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 31.ITALY DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 32.SPAIN DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 33.SPAIN DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 34.SPAIN DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 35.RUSSIA DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 36.RUSSIA DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 37.RUSSIA DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 38.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 39.REST OF EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 40.REST OF DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 41.DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 42.DIGITAL THERAPEUTICS MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 43.DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2018–2026 ($MILLION)
TABLE 44.ADA: COMPANY SNAPSHOT
TABLE 45.ADA: PRODUCT PORTFOLIO
TABLE 46.COGNIFIT: COMPANY SNAPSHOT
TABLE 47.COGNIFIT: OPERATING SEGMENT:
TABLE 48.COGNIFIT: PRODUCT PORTFOLIO
TABLE 49.CATERNA: COMPANY SNAPSHOT
TABLE 50.CATERNA: PRODUCT PORTFOLIO
TABLE 51.FITBIT: COMPANY SNAPSHOT
TABLE 52.FITBIT: PRODUCT PORTFOLIO
TABLE 53.KAIA HEALTH: COMPANY SNAPSHOT
TABLE 54.KAIA: OPERATING SEGMENT:
TABLE 55.KAIA: PRODUCT PORTFOLIO
TABLE 56.MEDTRONIC: COMPANY SNAPSHOT
TABLE 57.MEDTRONIC: OPERATING SEGMENTS
TABLE 58.MEDTRONIC: PRODUCT PORTFOLIO
TABLE 59.NOVARTIS: COMPANY SNAPSHOT
TABLE 60.NOVARTIS: OPERATING SEGMENTS
TABLE 61.NOVARTIS: PRODUCT PORTFOLIO
TABLE 62.RESMED: COMPANY SNAPSHOT
TABLE 63.RESMED: OPERATING SEGMENTS
TABLE 64.RESMED: PRODUCT PORTFOLIO
TABLE 65.SONORMED: COMPANY SNAPSHOT
TABLE 66.SONORMED: PRODUCT PORTFOLIO
TABLE 67.VOLUNTIS: COMPANY SNAPSHOT
TABLE 68.VOLUNTIS: OPERATING SEGMENTS
TABLE 69.VOLUNTIS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.DIGITAL THERAPEUTICS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS IN DIGITAL THERAPEUTICSS MARKET, 2018
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017–2019*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2017–2019* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2017–2019*
FIGURE 06.TOP PLAYER POSITIONING, 2018
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.HIGH BARGAINING POWER OF BUYERS
FIGURE 09.LOW THREAT OF SUBSTITUTION
FIGURE 10.MODERATE THREAT OF NEW ENTRANT
FIGURE 11.MODERATE COMPETITIVE RIVALRY
FIGURE 12.EUROPE DIGITAL THERAPEUTICS MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 13.EUROPE DIGITAL THERAPEUTICS MARKET BY APPLICATION
FIGURE 14.EUROPE DIGITAL THERAPEUTICS MARKET, BY PRODUCT
FIGURE 15.EUROPE DIGITAL THERAPEUTICS MARKET BY SALES CHANNEL
FIGURE 16.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY EMPLOYER,  2018–2026 ($MILLION)
FIGURE 17.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY HEALTHCARE PROVIDERS, 2018–2026 ($MILLION)
FIGURE 18.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-BUSINESS SALES CHANNEL, BY OTHERS,  2018–2026 ($MILLION)
FIGURE 19.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY PATIENTS, 2018–2026 ($MILLION)
FIGURE 20.EUROPE DIGITAL THERAPEUTICS MARKET FOR BUSINESS-TO-CONSUMERS SALES CHANNEL, BY CAREGIVERS, 2018–2026 ($MILLION)
FIGURE 21.FITBIT: NET SALES, 2016–2018 ($MILLION)
FIGURE 22.FITBIT: NET SALES BY REGION, 2018 (%)
FIGURE 23.MEDTRONIC: NET SALES, 2017–2019 ($MILLION)
FIGURE 24.MEDTRONIC: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 25.MEDTRONIC: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 26.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 28.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 29.RESMED: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.RESMED: REVENUE SHARE BY SEGMENT, 2019 (%)
FIGURE 31.RESMED: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 32.VOLUNTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 33.VOLUNTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 34.VOLUNTIS: REVENUE SHARE BY REGION, 2018 (%)

Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$4249
This license allows only one user to access the PDF.

1 - 5 User license

Electronic (PDF)
$4624
This license allows maximum 5 users to access the PDF

Enterprise License

Electronic (PDF)
$6449
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano Dimension

RELATED REPORTS

Dental Biomaterials Market
Global and China Dental Biomaterials Market Insights, Forecast to 2026

120 Pages
Type: Report
Code: QYRE-Othe-4P324
Wed Oct 21 05:35:33 UTC 2020

Add to Cart

3D Cell Culture Equipment and Tool Market
Global and China 3D Cell Culture Equipment and Tool Market Insights, Forecast to 2026

120 Pages
Type: Report
Code: QYRE-Othe-2U369
Tue Oct 20 10:19:22 UTC 2020

Add to Cart

0 Items
X
No items in the cart.
$0.0